Full Press Release Details
appoints biopharmaceutical senior executives
C. Russell and J. Martin Carroll as independent directors
RATON, Fla., March 18, 2015 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare
company, announced today the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll,
as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of
C. Russell served as CEO of Shire PLC, a biopharmaceutical company, from June 2008 until April 2013. Russell served as the chief
financial officer of Shire from 1999 to 2008 and also served as executive vice president of global finance. Prior to joining Shire,
Russell served at ICI, Zeneca and AstraZeneca PLC for 19 years, most recently in the role of vice president, corporate finance
at AstraZeneca. He is a chartered accountant, having qualified with what is now PriceWaterhouseCoopers LLP. Russell also serves
as a director of Mallinckrodt PLC and BioTime Inc. and as the chairman of the board of Revance Therapeutics Inc. Russell previously
served as a director of Shire PLC, Questcor Pharmaceuticals Inc. and InterMune Inc.
Martin Carroll served as president and CEO of Boehringer Ingelheim Corp. (U.S.) from 2003 until 2011. He also served as global
head of strategy and development for Boehringer Ingelheim (Germany) from 2009 through 2012 and served as chairman of the board
for a number of BI companies. Previously, Carroll held positions of increasing responsibility with Merck & Co. Inc. from 1976
to 2001, including manufacturing, international (Japan) and marketing and sales. He left Merck serving as its executive vice president
for customer marketing and sales of the U.S. Human Health Division. From 1972 to 1976, Carroll served in the United States Air
Force. Carroll has previously served on the board of directors for a number of organizations, including Accredo Health Group Inc.,
Vivus Inc., Durata Therapeutics Inc., and Gwynedd Mercy College, as well as PhRMA. He currently serves as a director of Mallinckrodt
are very pleased to add two new independent directors to our board. These biopharmaceutical industry leaders have a wealth of
experience in both serving as directors and in practical senior leadership responsibilities at successful organizations,"
said TherapeuticsMD CEO Robert G. Finizio. "This is an exciting time in our company's growth and development, and
we look forward to the insight of Angus and Marty."
commended the contributions of outgoing director Randall Stanicky, who currently serves as managing director of global equity
research, with a focus on specialty pharmaceuticals, at RBC Capital Markets.
would like to thank Randall for his help, contributions and commitment to TherapeuticsMD as a valued board member who will be
missed," Finizio said. "Randall's unique experience and extensive knowledge in this sector have been very helpful
as we advance our hormone therapy portfolio and gain greater leadership in the women's healthcare space. We sincerely thank
Randall for his tenure with us."
TherapeuticsMD, Inc.
Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its patented
SYMBODA technology platform, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery
of bio-identical hormones
through a variety of dosage forms and administration routes. The company's clinical development pipeline includes two phase
3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter
vitamins under the vitaMedMD and BocaGreenMD brands. More information is available at the following
press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are
not limited to, statements relating to TherapeuticsMD's objectives, plans and strategies as well as statements, other than
historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates
will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes,"
"may," "anticipates," "should," "intends," "plans," "will,"
"expects," "estimates," "projects," "positioned," "strategy" and similar
expressions and are based on assumptions and assessments made in light of management's experience and perception of historical
trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements
in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any
such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties, many of which are outside of the company's control. Important
factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements
are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form
8-K, and include the following: the company's ability to maintain or increase sales of its products; the company's
ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; the
length, cost and uncertain results of the company's clinical trials; the potential of adverse side effects or other safety
risks that could preclude the approval of the company's hormone therapy drug candidates; the company's reliance on
third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from
government authorities and health insurance companies for the company's products; the impact of product liability lawsuits;
the influence of extensive and costly government regulation; the volatility of the trading price of the company's common
stock and the concentration of power in its stock ownership. PDF copies of the company's historical press releases and financial
tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.